Science Corp implants PRIMA chip in first Stargardt disease patient

Science Corp implants PRIMA chip in first Stargardt disease patient

Lead – According to TechCrunch, Science Corporation implanted its PRIMA vision‑restoring chip in its first patient with Stargardt disease during a trial at Sydney Eye Hospital in Australia, aiming to expand the use of retinal prostheses as part of a broader brain‑computer interface (BCI) strategy.

Background and device – According to TechCrunch, Science Corporation’s PRIMA implant is a small, two‑by‑two‑millimetre chip placed on the back of the eye where photoreceptors have degenerated. The device functions as an artificial photoreceptor array that receives visual data from camera‑equipped glasses and transmits electrical signals to the optic nerve. The company states that the implant provides a high‑contrast, black‑and‑white patch of central vision, allowing patients to discern a few letters at a time.

First Stargardt patient – According to TechCrunch, the first Stargardt disease patient received the PRIMA implant in May as part of an ongoing clinical trial at Sydney Eye Hospital. During the patient’s initial rehabilitation session, he was able to see a single letter; in the second session, he read a whole word, demonstrating functional visual perception through the device.

Stargardt disease context – According to TechCrunch, Stargardt disease is an inherited disorder that gradually destroys the outer retina, leading to the death of light‑sensing cells while often sparing the inner retina that conveys signals to the brain. The condition creates a central blind spot that enlarges over time, and the article notes that approximately 150,000 people worldwide have lost vision because of the disease.

Procedure and patient experience – According to TechCrunch, implantation involves an hour‑long surgical procedure in which the chip is positioned on the degenerated retinal area. After surgery, patients wear glasses equipped with a camera that streams a live view to the implant. Hodak described the visual experience as “looking through a straw,” emphasizing that the current field of view is limited but sharp and high‑contrast.

Future development roadmap – According to TechCrunch, Science Corporation plans to enlarge the implant’s field of view by addressing the eye’s curvature and reducing electrode size, with a “next‑generation” device slated for human trials within the next year. The company projects that, over the next five years, its technology could approach native visual acuity.

Broader BCI vision – According to TechCrunch, CEO Max Hodak positioned the retinal implant within a larger BCI agenda, stating that the retina is part of the central nervous system and that cochlear, retinal, and motor prostheses are all forms of BCIs. He explained that the company’s ultimate aim is to develop neural engineering solutions that extend health span, noting that future BCIs may become common for people in their 60s or 70s.

Commercial status and other indications – According to TechCrunch, PRIMA is already commercially available in Europe for patients with geographic atrophy, an advanced form of age‑related macular degeneration. The company believes the same approach can be adapted to multiple retinal disorders, including the currently incurable Stargardt disease.

Parallel brain‑computer work – According to TechCrunch, Science Corporation’s BCI sensor differs from Neuralink’s design by resting on top of the brain rather than being inserted into brain tissue. The firm has hinted at forthcoming clinical indications for a neurodegenerative disease and stroke, suggesting that the sensor could monitor neurological activity or facilitate new cortical connections. Hodak indicated that the long‑term mission includes understanding how the brain creates the mind and eventually engineering artificial brains.

Analysis (Opinion) – The implantation of PRIMA in a Stargardt patient illustrates a pragmatic path for emerging BCI companies: leveraging a clear medical need to validate technology while pursuing more ambitious neural applications. If the next‑generation implant can widen its visual field without compromising safety, it may shift retinal prostheses from niche therapy toward broader adoption.

Conclusion – According to TechCrunch, Science Corporation’s successful implantation of the PRIMA chip in a Stargardt disease patient marks a milestone for retinal prosthetics and underscores the company’s strategy of using vision restoration as a stepping stone toward expansive brain‑computer interface solutions.

Source: TechCrunch

Frequently Asked Questions

What is the name of the vision‑restoring chip used by Science Corporation?

According to TechCrunch, the chip is called PRIMA.

Where was the first Stargardt disease patient implanted with PRIMA?

According to TechCrunch, the implantation took place at Sydney Eye Hospital in Australia.

How does the PRIMA implant convey visual information to the brain?

According to TechCrunch, the implant receives video from camera‑equipped glasses and converts it into electrical signals that stimulate the optic nerve, mimicking natural photoreceptor activity.

Source: TechCrunch — Read more

💻 Related Articles